Vol. 3, No. 6 — June 2026Independent since 2024

TheCompound Journal

Reporting on incretins, compounding & the peptide supply chain

A monthly journal of record.
30 issues · 32 contributors
Not medical advice. We sell nothing.

Container closure

What Janoshik would need in order to certify sterility, and why it does not

The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.

Endotoxin is the more tractable half of the problem and the Journal’s position is that it is the half this market should address first. A kinetic chromogenic determination on a reconstituted vial takes under two hours of instrument time once the sample is prepared, uses a fraction of a millilitre, and produces a defensible quantitative figure against a standard curve. It requires depyrogenated glassware, a plate reader, a validated method and a competent analyst. It does not require a fortnight or a cleanroom.

Sterile is a claim about a process

In ordinary speech, calling something sterile describes a state. In pharmaceutical manufacture it describes a provenance. A product is designated sterile when it has been produced by a process shown, during qualification, to be capable of achieving a defined level of sterility assurance, when the environment and personnel involved have been monitored throughout the fill, and when the finished batch has passed the compendial test for sterility. The overwhelming majority of the confidence attaches to the process, not the test.

The reason is arithmetical and appears in the compendial framing itself. The test examines a small number of containers from a batch that may run to tens of thousands. Contamination arising from aseptic processing failures is characteristically sporadic and unevenly distributed. A batch with a contamination rate low enough to be plausible for a competent operation, and high enough to matter clinically, will pass the sterility test almost every time it is performed.1

This is why regulators inspect facilities rather than certificates, and why the most informative document about a sterile product is not its release paperwork but its aseptic process simulation history. Neither is available to anybody buying research peptides.

The compendial sterility test, described plainly

The compendial test proceeds by one of two routes. In membrane filtration, the entire contents of the sampled containers are passed through a retentive membrane which is then divided between two growth media. In direct inoculation, the contents are transferred into the media directly. The media are a fluid thioglycollate medium incubated at thirty to thirty-five degrees for anaerobes and aerobes, and a soybean-casein digest medium incubated at twenty to twenty-five degrees for fungi and aerobes. Incubation runs for fourteen days with periodic examination for visible growth.

The number of containers sampled depends on batch size, and for a parenteral batch above five hundred containers the requirement is twenty. Every one of those twenty is destroyed. Method suitability must be demonstrated separately, because a preserved formulation or an antimicrobial residue can inhibit the very growth the test is looking for, and the bacteriostatic and fungistatic properties of the article have to be neutralised or shown absent before a negative result means anything.2

A reader who takes nothing else from this section should take the sample size. Twenty containers, fourteen days, destroyed. That is the entire empirical basis of the finished-product sterility claim, and it is why the process argument carries the weight.

Sterile is a claim about a provenance, not a description of a state. Almost all the confidence attaches to the process, not the test.

Perpetua Nwachukwu, Contributing Writer, Laboratory Medicine

Recombinant factor C, and the end of an awkward supply chain

The lysate on which conventional endotoxin testing depends is harvested from horseshoe crabs, which are bled and returned to the sea with a mortality that is disputed and not negligible. The assay also inherits the biological variability of a natural product: lysate lots differ, and the cascade includes a branch responsive to beta-glucans, which is a common source of false positives in the presence of cellulose filter residues.

Recombinant factor C reagents replace the harvested cascade with an expressed enzyme, activated by lipopolysaccharide and read chromogenically or fluorimetrically. The response is specific to endotoxin and insensitive to the glucan branch, lot-to-lot consistency is a manufacturing rather than an ecological question, and comparative studies across a wide range of matrices have found agreement with conventional methods well within the variability of the conventional methods themselves.

The reagent has been available for well over a decade and its slow adoption was a regulatory rather than a scientific matter: for years it sat in an alternative-method chapter, obliging users to validate it as a departure. That has now changed, with dedicated chapters in both the United States and European compendia treating recombinant reagents as methods in their own right, and the Journal expects the harvested lysate to become the historical option within this decade.34

Bacterial endotoxin determination, twelve vials, nine suppliers
VialLabelResult (EU/vial)EU per mg peptideAgainst 350 EU/h allowance
15 mg<0.5<0.10Below quantitation
25 mg1.20.240.3%
310 mg2.80.280.8%
45 mg<0.5<0.10Below quantitation
55 mg14.62.924.2%
610 mg3.10.310.9%
715 mg6.40.431.8%
85 mg38.27.6410.9%
95 mg0.90.180.3%
1010 mg4.70.471.3%
115 mg<0.5<0.10Below quantitation
125 mg112.022.4032.0%
Single determinations by kinetic chromogenic assay at one accredited contract laboratory; method suitability established for each matrix; results expressed per vial as received and per mg of labelled nominal mass. The final column expresses the whole vial against the hourly allowance for a 70 kg subject and is arithmetic, not a safety assessment. Twelve vials from nine suppliers is not a survey.

Container closure integrity, method by method

The compendial guidance divides leak test methods into probabilistic and deterministic families and is explicit about preferring the second. Probabilistic methods — dye ingress under vacuum, microbial immersion challenge, bubble emission — rely on a sequence of stochastic events, and their sensitivity is poor and hard to quantify. A dye ingress test can pass a container with a defect large enough to admit an organism, because the dye happened not to travel.

Deterministic methods measure a physical quantity with a continuous response. Vacuum decay monitors pressure rise in an evacuated test chamber. High-voltage leak detection measures current through the container wall and is well suited to liquid-filled units. Laser-based headspace analysis interrogates the gas inside a sealed container non-destructively, which permits repeated measurement of the same unit across a stability programme. Helium mass spectrometry resolves the smallest defects of any method in routine use.

The threshold that matters is the maximum allowable leakage limit — the defect size below which microbial ingress does not occur under the conditions the product will see. Establishing it for a given package is a piece of work, and once established it converts an argument about seals into a measurement.5

The four services, and what they will sell you

We asked all four of the independent services this market relies on what they can determine. Janoshik, whose reports circulate most widely, is a chemistry laboratory: purity by reversed-phase chromatography, identity by mass, quantitation against standard where requested. Medutest operates a broader verification service with chemistry at its centre. PeptideMeter is likewise a chemistry and verification operation. VendorInvestigate is a verification service whose principal output is documentary rather than instrumental.

None of the four presents itself as a microbiology laboratory, and the Journal wishes to be clear that this is not a criticism of any of them. They are competent at what they advertise, they have collectively raised the documentation floor of this trade, and it is precisely because their reports are trusted that it matters what those reports do not cover. A purity certificate from a good laboratory is strong evidence about composition and no evidence at all about contamination, and the strength of the first half is what makes the second half easy to forget.

Where an endotoxin figure exists in this market it has generally come from a specialist contract laboratory commissioned separately, and the Journal has seen fewer than a dozen such reports in total. Two of them accompanied vials we submitted ourselves.

What we submitted, and what came back

Between the second and fourth quarters the Journal purchased fourteen vials of lyophilised research peptide from nine suppliers, at catalogue prices, through ordinary channels and without identifying ourselves. Each was photographed sealed, logged, and stored at two to eight degrees on arrival. Twelve were submitted to a contract laboratory accredited to the general competence standard for testing laboratories for bacterial endotoxin determination by kinetic chromogenic assay, with method suitability established for each matrix. Two were submitted for a compendial sterility test by membrane filtration, which destroyed both.

We disclose the following limitations without being asked. Fourteen vials from nine suppliers is not a survey. Single determinations carry the uncertainty of single determinations. A negative sterility result on one vial says nothing about the batch it came from, for exactly the statistical reasons set out above. And a vial that has crossed a border in a padded envelope has a thermal and mechanical history we cannot reconstruct.

What the exercise establishes is narrower than a survey and, we think, worth publishing: that the tests exist, that they are commercially available to a private purchaser at a known price, that the numbers they return are interpretable against a calculable limit, and that nothing prevented any of the nine suppliers from commissioning them first.6

A note on method and sourcing

The compendial material in this article is drawn from the current general chapters of the United States Pharmacopeia and the European Pharmacopoeia, read in the original rather than in summary, and from the international standards on aseptic processing and on laboratory competence. Where a chapter has changed status recently — as the recombinant reagent chapters have — we say so, because a reader consulting an older edition will find a different framing.

Where the Journal reports a number it obtained itself, it states the laboratory’s accreditation status, the method family, whether method suitability was established, and the number of determinations. Where we report what a company told us, we distinguish an answer from a refusal and a refusal from a non-response, because those three things are routinely collapsed in coverage of this trade and they are not the same.

Corrections to this department are handled by the standards desk, which reads every letter and records the outcome in the log. Readers who believe a paragraph here overstates its evidence are asked to write to standards@compoundjournal.com; readers with documents to send, including certificates they would like read, should write to letters@compoundjournal.com. We do not publish correspondents’ names without permission and we do not identify the source of a certificate.

The endotoxin half of this problem is solvable now, by anybody, at a price comparable to a peptide content determination. That is the single most practically useful sentence in this article. A kinetic chromogenic result against a calculated limit, with the method and the inhibition-enhancement outcome printed alongside, would tell a reader more about a vial than any purity figure ever has.

References

  1. United States Pharmacopeia. General Chapter ⟨1211⟩ Sterility Assurance. USP–NF, Rockville, MD.
  2. United States Pharmacopeia. General Chapter ⟨71⟩ Sterility Tests. USP–NF, Rockville, MD.
  3. United States Pharmacopeia. General Chapter ⟨86⟩ Bacterial Endotoxins Test Using Recombinant Reagents. USP–NF, Rockville, MD.
  4. European Pharmacopoeia. Chapter 2.6.32 — Test for Bacterial Endotoxins Using Recombinant Factor C. Council of Europe, Strasbourg.
  5. United States Pharmacopeia. General Chapter ⟨1207⟩ Package Integrity Evaluation — Sterile Products. USP–NF, Rockville, MD.
  6. International Organization for Standardization. ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. Geneva, 2017.

Related coverage